Vivoryon Therapeutics N.V. Revenue and Competitors

Halle (Saale),

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Vivoryon Therapeutics N.V.'s estimated annual revenue is currently $4.6M per year.(i)
  • Vivoryon Therapeutics N.V.'s estimated revenue per employee is $201,000

Employee Data

  • Vivoryon Therapeutics N.V. has 23 Employees.(i)
  • Vivoryon Therapeutics N.V. grew their employee count by -8% last year.

Vivoryon Therapeutics N.V.'s People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$53.7M26716%N/AN/A
#2
$53.1M26421%N/AN/A
#3
$69.1M34426%N/AN/A
#4
$22.1M110-10%N/AN/A
#5
$151.8M75511%N/AN/A
#6
$63.9M31813%N/AN/A
#7
$29.9M14913%N/AN/A
#8
$1.7M17-6%$114.3MN/A
#9
$6.8M34-6%N/AN/A
#10
$12.5M62-9%N/AN/A
Add Company

What Is Vivoryon Therapeutics N.V.?

Vivoryon Therapeutics has an experienced discovery and development team with a strong track record in delivering therapies to patients. We have product-candidates in both clinical and preclinical development and are focusing on age-related diseases with unmet medical need. We are relentless and focused on putting patients at the center of everything we do and strive to develop life-changing medicines.

keywords:N/A

N/A

Total Funding

23

Number of Employees

$4.6M

Revenue (est)

-8%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Vivoryon Therapeutics N.V. News

2022-04-17 - Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Report Full Year 2021 Financial Results and Operational Progress on April 28, 2022

Halle (Saale) / Munich, Germany, April 21, 2022 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical...

2022-04-17 - Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to ...

DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Conference Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Participate at...

2022-04-13 - While shareholders of Vivoryon Therapeutics (AMS:VVY) are in the black over 3 years, those who bought a week ago aren't so fortunate

The last three months have been tough on Vivoryon Therapeutics N.V. (AMS:VVY) shareholders, who have seen the share price decline a rather...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$4.9M26-19%N/A
#2
$16.6M5637%N/A
#3
$9M6419%N/A
#4
$10.7M747%N/A
#5
$25M1395%N/A